For the second quarter of 2026, analysts anticipate Grifols to report a consensus revenue of $2.17 billion and an EPS of $0.27, while the current ADR price of $7.87 sits significantly below the average analyst price target of $10.87.
Investors are primarily focused on the company’s deleveraging trajectory, specifically watching for the net debt-to-EBITDA ratio to reach the 4.2x level following the successful divestiture of its Shanghai RAAS stake.
The report follows a period of intense organizational restructuring under new CEO Nacho Abia, who has moved to simplify corporate governance and eliminate related-party transaction concerns.
Market participants are also looking for sustained momentum in the Biopharma segment, where robust demand for immunoglobulins is expected to drive margin expansion and consistent free cash flow generation.